{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:05:28Z","timestamp":1781276728632,"version":"3.54.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biogen France SAS"},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-COHO-002"],"award-info":[{"award-number":["ANR-10-COHO-002"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12325-024-03092-5","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T14:44:23Z","timestamp":1739976263000},"page":"1760-1782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct04756687","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7197-7578","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"de S\u00e8ze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Labauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Liblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Suchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Vukusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Mathey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelie","family":"Ruet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helene","family":"Zephir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Defer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Axel","family":"Laplaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Clavelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Thouvenot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Heinzlef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Pelletier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Giannesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Casez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Bourre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abir","family":"Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Magy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Camdessanch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e8s","family":"Doghri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Labeyrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina","family":"Hankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Neau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Pottier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Dobay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-4777","authenticated-orcid":false,"given":"Marilyn","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7744-4207","authenticated-orcid":false,"given":"Marta","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Rollot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"3092_CR1","unstructured":"European Medicines Agency. TECFIDERA\u00ae (dimethyl fumarate) Summary of Product Characteristics. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tecfidera-epar-product-information_en.pdf. Accessed 25 May 2023."},{"key":"3092_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.msard.2018.02.028","volume":"22","author":"SL Cohan","year":"2018","unstructured":"Cohan SL, Moses H, Calkwood J, et al. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: a multicenter retrospective observational study (STRATEGY). Mult Scler Relat Disord. 2018;22:27\u201334. https:\/\/doi.org\/10.1016\/j.msard.2018.02.028.","journal-title":"Mult Scler Relat Disord"},{"key":"3092_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","volume":"6","author":"RJ Fox","year":"2016","unstructured":"Fox RJ, Chan A, Gold R, et al. Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: patient management considerations. Neurol Clin Pract. 2016;6:220\u20139. https:\/\/doi.org\/10.1212\/CPJ.0000000000000238.","journal-title":"Neurol Clin Pract"},{"key":"3092_CR4","doi-asserted-by":"publisher","first-page":"175628642091500","DOI":"10.1177\/1756286420915005","volume":"13","author":"R Gold","year":"2020","unstructured":"Gold R, Arnold DL, Bar-Or A, et al. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years\u2019 follow-up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord. 2020;13:1756286420915005. https:\/\/doi.org\/10.1177\/1756286420915005.","journal-title":"Ther Adv Neurol Disord"},{"key":"3092_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1352458516649037","volume":"23","author":"R Gold","year":"2017","unstructured":"Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Mult Scler. 2017;23:253\u201365. https:\/\/doi.org\/10.1177\/1352458516649037.","journal-title":"Mult Scler"},{"key":"3092_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1114287.","journal-title":"N Engl J Med"},{"key":"3092_CR7","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/j.clinthera.2018.10.011","volume":"40","author":"K Kresa-Reahl","year":"2018","unstructured":"Kresa-Reahl K, Repovic P, Robertson D, Okwuokenye M, Meltzer L, Mendoza JP. Effectiveness of delayed-release dimethyl fumarate on clinical and patient-reported outcomes in patients with relapsing multiple sclerosis switching from glatiramer acetate: RESPOND, a prospective observational study. Clin Ther. 2018;40:2077\u201387. https:\/\/doi.org\/10.1016\/j.clinthera.2018.10.011.","journal-title":"Clin Ther"},{"key":"3092_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1206328.","journal-title":"N Engl J Med"},{"key":"3092_CR9","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/13524585211037909","volume":"28","author":"R Gold","year":"2022","unstructured":"Gold R, Arnold DL, Bar-Or A, et al. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results. Mult Scler. 2022;28:801\u201316. https:\/\/doi.org\/10.1177\/13524585211037909.","journal-title":"Mult Scler"},{"key":"3092_CR10","doi-asserted-by":"publisher","first-page":"e1724","DOI":"10.1212\/WNL.0000000000007262","volume":"92","author":"D Mehta","year":"2019","unstructured":"Mehta D, Miller C, Arnold DL, et al. Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice. Neurology. 2019;92:e1724\u201338. https:\/\/doi.org\/10.1212\/WNL.0000000000007262.","journal-title":"Neurology"},{"key":"3092_CR11","doi-asserted-by":"publisher","first-page":"205521732091861","DOI":"10.1177\/2055217320918619","volume":"6","author":"G Buckle","year":"2020","unstructured":"Buckle G, Bandari D, Greenstein J, et al. Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis. Mult Scler J Exp Transl Clin. 2020;6:2055217320918619. https:\/\/doi.org\/10.1177\/2055217320918619.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"3092_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1177\/1352458520937282","volume":"27","author":"EE Longbrake","year":"2021","unstructured":"Longbrake EE, Mao-Draayer Y, Cascione M, et al. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Mult Scler. 2021;27:883\u201394. https:\/\/doi.org\/10.1177\/1352458520937282.","journal-title":"Mult Scler"},{"key":"3092_CR13","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1002\/ana.26328","volume":"91","author":"M Diebold","year":"2022","unstructured":"Diebold M, Galli E, Kopf A, et al. Immunological predictors of dimethyl fumarate-induced lymphopenia. Ann Neurol. 2022;91:676\u201381. https:\/\/doi.org\/10.1002\/ana.26328.","journal-title":"Ann Neurol"},{"key":"3092_CR14","doi-asserted-by":"publisher","first-page":"2147055","DOI":"10.1080\/19490976.2022.2147055","volume":"14","author":"M Diebold","year":"2022","unstructured":"Diebold M, Meola M, Purushothaman S, et al. Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis. Gut Microbes. 2022;14:2147055. https:\/\/doi.org\/10.1080\/19490976.2022.2147055.","journal-title":"Gut Microbes"},{"key":"3092_CR15","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1007\/s00415-021-10412-0","volume":"268","author":"M Lucchini","year":"2021","unstructured":"Lucchini M, Prosperini L, Buscarinu MC, et al. Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis. J Neurol. 2021;268:2238\u201345. https:\/\/doi.org\/10.1007\/s00415-021-10412-0.","journal-title":"J Neurol"},{"key":"3092_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3389\/fgene.2019.01039","volume":"10","author":"D Sangurdekar","year":"2019","unstructured":"Sangurdekar D, Sun C, McLaughlin H, et al. Genetic study of severe prolonged lymphopenia in multiple sclerosis patients treated with dimethyl fumarate. Front Genet. 2019;10:1039. https:\/\/doi.org\/10.3389\/fgene.2019.01039.","journal-title":"Front Genet"},{"key":"3092_CR17","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1212\/CPJ.0000000000000800","volume":"10","author":"A Chan","year":"2020","unstructured":"Chan A, Rose J, Alvarez E, et al. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. Neurol Clin Pract. 2020;10:510\u20139. https:\/\/doi.org\/10.1212\/CPJ.0000000000000800.","journal-title":"Neurol Clin Pract"},{"key":"3092_CR18","doi-asserted-by":"publisher","first-page":"175628641984345","DOI":"10.1177\/1756286419843450","volume":"12","author":"M Briner","year":"2019","unstructured":"Briner M, Bagnoud M, Miclea A, et al. Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age. Ther Adv Neurol Disord. 2019;12:1756286419843450. https:\/\/doi.org\/10.1177\/1756286419843450.","journal-title":"Ther Adv Neurol Disord"},{"key":"3092_CR19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jnnp.55.8.671","volume":"55","author":"C Confavreux","year":"1992","unstructured":"Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1992;55:671\u20136. https:\/\/doi.org\/10.1136\/jnnp.55.8.671.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3092_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/1352458518815602","volume":"26","author":"S Vukusic","year":"2020","unstructured":"Vukusic S, Casey R, Rollot F, et al. Observatoire Francais de la Sclerose en Plaques (OFSEP): a unique multimodal nationwide MS registry in France. Mult Scler. 2020;26:118\u201322. https:\/\/doi.org\/10.1177\/1352458518815602.","journal-title":"Mult Scler"},{"key":"3092_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102781","volume":"49","author":"R Garbo","year":"2021","unstructured":"Garbo R, Lorenzut S, Del Negro I, et al. Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment. Mult Scler Relat Disord. 2021;49:102781. https:\/\/doi.org\/10.1016\/j.msard.2021.102781.","journal-title":"Mult Scler Relat Disord"},{"key":"3092_CR22","doi-asserted-by":"publisher","first-page":"205521732211324","DOI":"10.1177\/20552173221132469","volume":"8","author":"J Lyons","year":"2022","unstructured":"Lyons J, Hughes R, McCarthy K, et al. Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate. Mult Scler J Exp Transl Clin. 2022;8:20552173221132469. https:\/\/doi.org\/10.1177\/20552173221132469.","journal-title":"Mult Scler J Exp Transl Clin"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03092-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03092-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03092-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T07:09:39Z","timestamp":1742713779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03092-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3092"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03092-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J\u00e9r\u00f4me de S\u00e8ze: consultant, advisory boards, and scientific meetings for Alexion, Biogen, CSL Behring, Genzyme\/Sanofi, Horizon Therapeutics, LFB, Janssen, Novartis, Roche, and Teva. Pierre Labauge: congresses and research grants from Biogen, BMS, Merck, Novartis, Sanofi Genzyme, and Teva. Roland Liblau: research grants from BMS, GSK, and Roche; speaker fees from Biogen, Merck, Novartis, Roche, and Sanofi Genzyme. Mikel Martinez: no conflicts of interest to disclose. Thibault Moreau: research support and consultancy fees from Biogen, Merck, Novartis, Roche, and Sanofi. Laurent Suchet: consulting fees from\u00a0Biogen, BMS-Celgene, Merck, Novartis, Roche, and Sanofi Genzyme;\u00a0honoraria from Novartis and Sanofi. Patrick Vermersch: honoraria from AB Science, Ad Scientiam, Biogen, BMS-Celgene, Imcyse, Janssen, Merck, Novartis, Roche, Sanofi Genzyme, and Teva; research support from Novartis, Roche, and Sanofi Genzyme. Sandra Vukusic: lecturing fees, travel grants, and research support from Biogen, BMS-Celgene, Janssen, Merck, Novartis, Roche, Sandoz, and\u00a0Sanofi Genzyme. Guillaume Mathey: no conflicts of interest to disclose. Laure Michel: no conflicts of interest to disclose. Jonathan Ciron: consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Biogen, Horizon Therapeutics, Novartis, Merck, Roche, and Sanofi Genzyme. Aurelie Ruet: received honoraria for meeting speaking from Alexion, Horizon Therapeutics, Merck, and Sanofi Genzyme; received support for traveling from Biogen, Merck, and Novartis. Her institution received research grants from Biogen, BMS, Roche, and Sanofi Genzyme. Elisabeth Maillart: consulting and lecturing fees from Alexion, Biogen, Horizon, Janssen, Merck Serono, Novartis, Roche, Sandoz, Sanofi Genzyme, and Teva Pharmaceuticals; and research support from Biogen. Helene Zephir: consulting or lectures, and invitations for national and international congresses, from Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, and Teva; research support from Roche and Teva; and academic research grants from Acad\u00e9mie de M\u00e9decine, ARSEP Foundation, FHU Imminent, and LFSEP. Caroline Papeix: no conflicts of interest to disclose. Gilles Defer: consulting and lecturing fees for Biogen, Genzyme, Merck Serono, Novartis, Roche, and Teva; and funding for travel from Biogen, Merck Serono, Novartis, Sanofi Genzyme, and Teva. Institution granted for research supporting from Biogen, Genzyme, Merck Serono, and Novartis. Mikael Cohen: has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ad Scientiam, Alexion, Biogen, Celgene-BMS, Horizon Therapeutics, Janssen, Merck, Roche, and Sanofi. David Axel Laplaud: served on scientific advisory boards for Alexion, Biogen, BMS, Janssen, Merck, Novartis, Roche, and Sanofi; received conference travel support and\/or speaker honoraria from Alexion, Biogen, BMS, Merck, Novartis, Roche, and Sanofi; and received research support from Agence Nationale de la Recherche, Fondation ARSEP, and Fondation EDMUS.\u200b Eric Berger: honoraria and consulting fees from Biogen, Genzyme, Novartis, Roche, Sanofi Aventis, and Teva Pharma. Pierre Clavelou: consulting and lecturing fees, travel grants, and unconditional research support from Biogen, Janssen, Medday, Merck, Novartis, Roche, Sanofi Genzyme, and Teva Pharma. Eric Thouvenot: consulting and lecturing fees, travel grants, or unconditional research support from Actelion, Biogen, Janssen, Merck Serono, Novartis, Roche, and Sanofi. Olivier Heinzlef: consulting and lecturing fees from Almirall, Bayer Schering, Biogen Idec, Genzyme, Merck, Novartis, and Teva; travel grants from Biogen Idec, Genzyme, Merck Serono, Novartis, and Teva; and research support from Roche, Merck, and Novartis. Jean Pelletier: no conflicts of interest to disclose. Claire Giannesini: no conflicts of interest to disclose. Olivier Casez: Biogen (personal fees), Janssen (personal fees), Merck (personal fees, non-financial support [traveling\/congress]), Novartis (personal fees, non-financial support [traveling\/congress]), Roche (personal fees, non-financial support [traveling\/congress]), and Sanofi (personal fees). Bertrand Bourre: served on scientific advisory board for Alexion, Biogen, BMS, Horizon, Janssen, Merck, Novartis, Roche, Sandoz, and Sanofi; and received funding for travel and honoraria from Alexion, Janssen, Merck, Novartis, Roche, and Sanofi. Abir Wahab: provided expert testimony for Roche and received travel grants from Biogen. Laurent Magy: no conflicts of interest to disclose. Jean-Philippe Camdessanch\u00e9: consulting and lecturing fees from Akcea, Alexion, Alnylam, Argenx, Biogen, Bristol Myers Squibb, CSL Behring, Genzyme, Grifols, Laboratoire Fran\u00e7ais des Biotechnologies, Merck Serono, Natus, Novartis, Pfizer, Pharmalliance, SNF-Floerger, Teva, and UCB Pharma; travel grants from Akcea, Alexion, Alnylam, Argenx, Biogen, CSL Behring, Genzyme, Grifols, Laboratoire Fran\u00e7ais des Biotechnologies, Merck Serono, Natus, Novartis, Pfizer, SNF-Floerger, and Teva. In\u00e8s Doghri: no conflicts of interest to disclose. C\u00e9line Labeyrie: no conflicts of interest to disclose. Karolina Hankiewicz: no conflicts of interest to disclose. Jean-Philippe Neau: no conflicts of interest to disclose. Corinne Pottier: support from Alexion, Biogen, Merck, Novartis, Roche, and Teva. Pamela Dobay, Seth Levin, Marilyn Gros, Marta Ruiz: employees of\u00a0Biogen and may own stock in the company. Hanyue Li: employee of Biogen and may have owned stock in the company\u00a0at the time this work was conducted. Fabien Rollot: no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"In accordance with French legislation, the OFSEP cohort was approved by the national data protection agency (Commission Nationale de l\u2019Informatique et des Libert\u00e9s; authorization request 914066v3) and the French ethical committee (Comit\u00e9 de Protection des Personnes: reference 2019-A03066-51). All patients in the OFSEP cohort provided informed consent to have their medical data shared anonymously for research purposes. Appropriate research information on the OFSEP registry research cohort is available on the OFSEP website [, ]. After 1\u00a0month without objections from the patient, patient data were extracted for analysis. As per French legislation (\u201cLoi Informatique et Libert\u00e9s\u201d No. 78\u201317 on January 6, 1978, modified by Law No. 2016\u201341 on January 26, 2016), LymphoTEC was registered on ClinicalTrials.gov (NCT04756687) and was compliant with the \u201cFrench Methodology of reference MR-004\u201d. The study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}